Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

PCPaul ChauvetGMGabriel E. MonsalveALAurore Lavigné

Discussion

Loading...

Member takes

Overview

Analysis identifies a CD8+ T-cell biomarker profile predicting treatment failure in large B-cell lymphoma patients, suggesting targeted strategies may improve treatment outcomes.

Key Points

  • CD8+ T-cell profile predicts resistance to treatment in large B-cell lymphoma, emphasizing the role of baseline biomarkers.
  • Complete response rates were observed at 53.3%, 55.0%, and 57.6% over time with 71.7% having progressive disease.
  • Single-cell RNA sequencing analysis provided insights into T cell functionality and patient response to CAR T-cell therapy.
  • Study highlights the importance of identifying CD8+ T cell phenotypes for optimal patient stratification and therapy selection.

Cite This Study

Chauvet et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d62ehttps://doi.org/10.1182/blood-2025-1945
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)2025
  2. 2Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel2025
  3. 3Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy2025
  4. 4Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence2025 · 1 citations
  5. 5Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma2025